Anyone up on the lawsuit that is in process against Regulus for supposedly misleading the public?
This is from Yahoo RGLS stock page/GlobeNewswire 3/31/17:
”The Complaint states that throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported.
If you purchased shares of Regulus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.”
~~~~~~~~~~~~~~~~~~~~~~~~
I own a few shares, puchased during those months. Wonder how legitimate the claims are and what the state of RGLS is now. Dr. KSS, are you within earshot?
Thanks!

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.